Blog
RSS FeedPosted by Michael Wonder on 05 Apr 2017
Report on the collection of under co-payment data - 2015-16
5 April 2017 - The report on the collection of under co-payment data for 2015-16 is now available. ...
Posted by Michael Wonder on 04 Apr 2017
Changes to NICE drug appraisals: what you need to know
4 April 2017 - The NHS is under unprecedented financial pressure, so it’s more important than ever for it to ...
Posted by Michael Wonder on 04 Apr 2017
Brenzys lists on the Australian PBS and Pfizer denied discovery of documents to establish grounds for patent infringement
4 April 2017 - As of 1 April 2017, Samsung Bioepis' Brenzys, a biosimilar to Pfizer's Enbrel (etanercept), will join ...
Posted by Michael Wonder on 03 Apr 2017
Stan Zemanek’s widow Marcella calls for more funding into rare cancers
2 April 2017 - The widow of radio broadcaster Stan Zemanek has made an emotional plea to the federal government ...
Posted by Michael Wonder on 02 Apr 2017
Were NHS chiefs right to deny 'miracle' life-giving pancreatic cancer drug? As NICE reviews Abraxane, the Mail reveals there were concerns the study results were 'inappropriately rosy' three years ago
2 April 2017 - Abraxane doubled life expectancy of terminally ill pancreatic cancer patients. ...
Posted by Michael Wonder on 02 Apr 2017
300 cancer patients given a chance to live thanks to immunotherapy drugs
1 April 2017 - More than 300 people have been given another chance at life at a cost of more ...
Posted by Michael Wonder on 02 Apr 2017
Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia
1 April 2017 - Institutional payers for pharmaceuticals worldwide appear to be increasingly negotiating confidential discounts off of the official list ...
Posted by Michael Wonder on 01 Apr 2017
Agenda for 5 April 2017 TC meeting
31 March 2017 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 01 Apr 2017
Schedule of Pharmaceutical Benefits - 1 April 2017
1 April 2017 - The 1 April 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Mar 2017
pERC publishes initial recommendation for Roche's Gazyva
30 March 2017 - The outcome relates to the use of obinutuzumab in combination with chemotherapy followed by obinutuzumab monotherapy ...
Posted by Michael Wonder on 31 Mar 2017
Biosimilar awareness initiative - April 2017 update
1 April 2017 - The Initiative was announced in May 2015 as part of the Pharmaceutical Benefits Scheme Access and Sustainability ...
Posted by Michael Wonder on 31 Mar 2017
Proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) in the Hospital medicines list
31 March 2017 - PHARMAC is seeking feedback on a proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) through a provisional ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final recommendation for Sanofi Genzyme's Caprelsa
30 March 2017 - The recommendation relates to the use of vandetanib for the treatment of symptomatic and/or progressive medullary ...
Posted by Michael Wonder on 30 Mar 2017
The hidden cost keeping your health insurance premiums high
30 March 2017 - Private health insurance costs for everyone could drop dramatically if the Federal Government tackled murky practices relating ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final outcome for Amgen's Kyprolis
30 March 2017 - The outcome relates to the use of carfilzomib in combination with dexamethasone by patients with relapsed ...